EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity

Yu Nakagama iD, Katherine Candray, Natsuko Kaku, Yuko Komase, Maria-Virginia Rodriguez-Funes, Rhina Dominguez, Tomoya Tsuchida, Hiroyuki Kunishima, Etsuko Nagai, Eisuke Adachi, Dieudonné Mumba Ngoyi, Mari Yamasue und 15 weitere

The Journal of Infectious Diseases · 2023

DOI: 10.1093/infdis/jiac492 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Yu Nakagama und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. Hauptthemen laut MEDLINE: BNT162 Vaccine, COVID-19. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society, for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cross-neutralizing capacity of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants is important in mitigating (re-)exposures. Role of antibody maturation, the process whereby selection of higher affinity antibodies augments host immunity, to determine SARS-CoV-2 neutralizing capacity was investigated.

Methods

Sera from SARS-CoV-2 convalescents at 2, 6, or 10 months postrecovery, and BNT162b2 vaccine recipients at 3 or 25 weeks postvaccination, were analyzed. Anti-spike IgG avidity was measured in urea-treated ELISAs. Neutralizing capacity was assessed by surrogate neutralization assays. Fold change between variant and wild-type neutralization inferred the breadth of neutralizing capacity.

Results

Compared with early-convalescent, avidity indices of late-convalescent sera were significantly higher (median, 37.7 [interquartile range 28.4–45.1] vs 64.9 [57.5–71.5], P < .0001). Urea-resistant, high-avidity IgG best predicted neutralizing capacity (Spearman r = 0.49 vs 0.67 [wild-type]; 0.18–0.52 vs 0.48–0.83 [variants]). Higher-avidity convalescent sera better cross-neutralized SARS-CoV-2 variants (P < .001 [Alpha]; P < .01 [Delta and Omicron]). Vaccinees only experienced meaningful avidity maturation following the booster dose, exhibiting rather limited cross-neutralizing capacity at week 25.

Conclusions

Avidity maturation was progressive beyond acute recovery from infection, or became apparent after the booster vaccine dose, granting broader anti-SARS-CoV-2 neutralizing capacity. Understanding the maturation kinetics of the 2 building blocks of anti-SARS-CoV-2 humoral immunity is crucial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BNT162 VaccineCOVID-19HumansAntibody AffinityCOVID-19 SerotherapySARS-CoV-2UreaVaccinationImmunoglobulin GAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirus

Stichwörter der Autor:innen

SARS-CoV-2antibody maturationavidityneutralization breadthvariants of concern

Substanzen

BNT162 VaccineUreaImmunoglobulin GAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Centro Nacional de Investigaciones Científicas de El Salvador, San Salvador, El Salvador.
  • Department of Respiratory Internal Medicine, St Marianna University, Yokohama Seibu Hospital, Yokohama, Japan.
  • National Rosales Hospital, San Salvador, El Salvador.
  • El Salvador National Institute of Health, San Salvador, El Salvador.

ORCID-Profile: Yu Nakagama, Yasutoshi Kido

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society
  • for the Promotion of Science
  • Osaka Metropolitan University
  • Shinya Yamanaka Laboratory

Zitieren

APA

Nakagama, Y., Candray, K., Kaku, N., Komase, Y., Rodriguez-Funes, M. V., Dominguez, R., Tsuchida, T., Kunishima, H., Nagai, E., Adachi, E., Ngoyi, D. M., Yamasue, M., Komiya, K., Hiramatsu, K., Uemura, N., Sugiura, Y., Yasugi, M., Yamagishi, Y., Mikamo, H., …, & Kido, Y. (2023). Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiac492

Vancouver

Nakagama Y, Candray K, Kaku N, Komase Y, Rodriguez-Funes MV, Dominguez R, et al. Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiac492

BibTeX
@article{Nakagama2023,
  author = {Nakagama, Yu and Candray, Katherine and Kaku, Natsuko and Komase, Yuko and Rodriguez-Funes, Maria-Virginia and Dominguez, Rhina and Tsuchida, Tomoya and Kunishima, Hiroyuki and Nagai, Etsuko and Adachi, Eisuke and Ngoyi, Dieudonné Mumba and Yamasue, Mari and Komiya, Kosaku and Hiramatsu, Kazufumi and Uemura, Naoto and Sugiura, Yuki and Yasugi, Mayo and Yamagishi, Yuka and Mikamo, Hiroshige and Shiraishi, Satoshi and Izumo, Takehiro and Nakagama, Sachie and Watanabe, Chihiro and Nitahara, Yuko and Tshibangu-Kabamba, Evariste and Kakeya, Hiroshi and Kido, Yasutoshi},
  title = {Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity},
  journal = {The Journal of Infectious Diseases},
  year = {2023},
  doi = {10.1093/infdis/jiac492}
}
Kostenlos starten →